CEA als biomarker bij longcarcinoom
Recruiting
- Conditions
- (N)SCLCBiomarkerCEA
- Registration Number
- NL-OMON25617
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
I. Advanced (N)SCLC patients who received conventional chemotherapy, targeted therapy or immunotherapy between 2009-2016.
II. CEA levels available prior to treatment (baseline), on week 3, 6 and 12.
Exclusion Criteria
Subjects who do not meet inclusion criteria.
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation of CEA decline (when CEA initially is increased (>5.0 ng/mL)) and OR (conform RECIST 1.1 criteria).
- Secondary Outcome Measures
Name Time Method I. The correlation of decline of CEA levels and overall survival (OS).<br /><br>II. The correlation of decline of CEA levels and the occurrence of brain metastases.<br /><br>III. The correlation of decline of CEA levels and OR on different treatment strategies (conventional chemotherapy, targeted therapy and immunotherapy).